Previous 10 | Next 10 |
home / stock / bpmuf / bpmuf news
Basilea Pharmaceutica AG press release (OTC:BPMUF): FY GAAP EPS of -CHF 0.58. Revenue of CHF 148.1M (+16.1% Y/Y). For 2022, Total revenue of CHF 106M – 112M; Cresemba & Zevtera related revenue is expected to amount to CHF 98M – 104M. Net cash used in operating acti...
The following slide deck was published by Basilea Pharmaceutica AG in conjunction with their 2021 Q2 earnings call. For further details see: Basilea Pharmaceutica AG 2021 Q2 - Results - Earnings Call Presentation
Basilea Pharmaceutica AG (BPMUF) Q2 2021 Earnings Conference Call August 17, 2021, 10:00 ET Company Participants David Veitch - CEO Adesh Kaul - CFO Marc Engelhardt - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Brian White - Calvine Partners Bob Pooler - Valuation ...
Basilea Pharmaceutica AG (BPMUF) Q4 2020 Earnings Conference Call February 16, 2021 10:00 A.M. ET Company Participants David Veitch - Chief Executive Officer Adesh Kaul - Chief Financial Officer Marc Engelhardt - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Arsene G...
The following slide deck was published by Basilea Pharmaceutica AG in conjunction with their 2020 Q4 earnings call. For further details see: Basilea Pharmaceutica AG 2020 Q4 - Results - Earnings Call Presentation
Basilea Pharmaceutica AG (BPMUF): FY GAAP EPS of -CHF1.43.Revenue of CHF127.6MPress Release For further details see: Basilea Pharmaceutica AG reports FY 2020 results
Basilea Pharmaceutica (BPMUF) and its license partner Pfizer (PFE) down 0.2% premarket,have submitted a marketing application seeking approval for the antifungal isavuconazole (Cresemba) for the treatment of adult patients with invasive aspergillosis to the ...
The following slide deck was published by Basilea Pharmaceutica AG in conjunction with this Read more ...
The following slide deck was published by Basilea Pharmaceutica AG in conjunction with their 2020 Q2 earnings Read more ...
Basilea Pharmaceutica AG (BPMUF) Q2 2020 Results Conference Call August 11, 2020 10:00 AM ET Company Participants David Veitch - Chief Executive Officer Adesh Kaul - Chief Financial Officer Dr. Marc Engelhardt - Chief Medical Officer Conference Call Participants Louise Chen...
News, Short Squeeze, Breakout and More Instantly...
Basilea Pharm Ag Akt Shs Company Name:
BPMUF Stock Symbol:
OTCMKTS Market:
China Yuchai International Limited (CYD) is expected to report for Q1 2024 Avid Bioservices Inc. (CDMO) is expected to report $0.03 for Q4 2024 Derwent London Plc (DWVYF) is expected to report for Q1 2024 Fresnillo Plc (FNLPF) is expected to report for Q1 2024 Basilea Pharmaceutic...
GreenTree Hospitality Group Ltd. American depositary shares each representing one Class A (GHG) is expected to report for Q1 2024 Air T Inc. (AIRT) is expected to report for Q4 2024 Alimentation-Couche Tard Inc. - Class A (Multiple Voting) (ANCTF) is expected to report for Q4 2024 Man...
Allschwil, Switzerland, June 20, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement w...